Scholar Rock Holding
Update in progressSRRK (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Scholar Rock is a Cambridge, MA biopharmaceutical company focused on rare neuromuscular diseases, including spinal muscular atrophy (SMA). It uses a proprietary platform to target latent growth factors in the TGF-β superfamily with monoclonal antibodies. Lead programs: Apitegromab, a myostatin activation inhibitor in Phase 2 for SMA and FSHD; SRK-439 in Phase 1; SRK-181 as a latent TGF-β1 inhibitor in later development; plus preclinical SRK-373 and SRK-256.
Company score
- Sentiment
- 0.14
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.03
- Governance
- -0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.01
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.07
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!